Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (“ Innate ” or the “ Company ”) today announced that members of its senior management team are scheduled to participate in the following upcoming...

Pursuant to the article L. 233-8 II of the French “Code de Commerce” and the article 223-16 of the French stock-market authorities (Autorité des Marchés Financiers, or “ AMF ”) General Regulation...

Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (“ Innate ” or the “ Company ”), today announced that a planned futility interim analysis of the INTERLINK-1 Phase 3 study sponsored by AstraZeneca...

Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (“ Innate ” or the “ Company ”) today announced that members of its senior management team are scheduled to participate in the following upcoming...

IPH6401/SAR’514 is a BCMA-targeting NK cell engager using Sanofi’s proprietary CROSSODILE ® multi-functional platform. It was developed jointly and benefits from the dual NK targeting of Innate’s...

Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (“ Innate ” or the “ Company ”) today announced that its investor relation team will participate in the following upcoming investor conference...

Anti-CD39 monoclonal antibody IPH5201 advances to Phase 2 study in lung cancer Innate to receive $5M milestone payment from AstraZeneca Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (“ Innate ”...

Appointment of Dr Sally Bennett to the Supervisory Board Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (“ Innate ” or the “ Company ”) announced the voting results of its shareholders at the...